Form 4 for MIRM Mirum Pharmaceuticals, Inc.

Accepted 2026-01-27 00:00:00 ET · period of report 2026-01-23 · accession 0001365617-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2026-01-27	2026-01-23	MIRM	Heron Patrick J	Dir	J - Other	—	+159.3K	327.6K	+95%	—
I	2026-01-27	2026-01-23	MIRM	Heron Patrick J	Dir	P - Purchase	$68.48	+131.4K	459.0K	+40%	+$9.00M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-01-23	J	A	159,277	—	327,585	I By Frazier Life Sciences X, L.P.	—	—	(F1) Frazier Life Sciences X, L.P. received these shares in connection with merger of Bluejay Therapeutics, Inc. into the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's Common Stock was $94.29 per share. (F2) The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
2	Common	Common Stock	2026-01-23	P	A	131,425	$68.48	459,010	I By Frazier Life Sciences X, L.P.	—	—	(F2) The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.